Advertisement

Picture Berlin Partner Life Sciences Report 2019/2020 Brandenburg 650x80px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 3101 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 12 13 14 ... 30 31 32  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Scailyte–SEVERAL: investment, 201901 seed financing round CHF2.75m incl new investors Swisscom Ventures + Zürcher Kantonalbank 2019-01-22
Scailyte–Swisscom: investment, 201901 seed financing round totalling CHF2.75m incl new investors Swisscom Ventures + Zürcher Kantonalbank 2019-01-22
Scailyte–Zürcher Kantonalbank: investment, 201901 seed financing round totalling CHF2.75m incl new investors Swisscom Ventures + Zürcher Kantonalbank 2019-01-22
Link Health–Marinomed: drug delivery technology, 201901– collab registration + distribution of Marinosolv products in China by Link Health 2019-01-21
Medison Pharma–Alnylam: RNAi therapeutics, 201901– commcercialisation excl of Onpattro + other RNAi drugs from Alnylam in Israel 2019-01-21
Miltenyi Biotec–Univ Duisburg-Essen: imaging technology, 201901 acquisition process for opitcal clearing of biological samples for miccrosopy 2019-01-17
Mologen–SEVERAL: credit, 201901–202701 convertible bonds €2.7m at 6% incl existing shareholders 2019-01-17
Mecuris–Bavaria (govt): investment, 201901 financing round Series A totalling €3.6m incl existing investor Bayern Kapital GmbH 2019-01-16
Mecuris–High-Tech Gründerfonds: investment, 201901 financing round Series A totalling €3.6m incl existing investor HTGF 2019-01-16
Mecuris–Mulcan: investment, 201901 financing round Series A totalling €3.6m incl new investor MII Mulcan International Investments GmbH 2019-01-16
Mecuris–OTHER: investment, 201901 financing round Series A totalling €3.6m incl new investor one of largest German hospital chains 2019-01-16
Mecuris–SEVERAL: investment, 201901 financing round Series A €3.6m incl Bayern Kapital + HTGF + Vesalius Biocapital + Mulcan et al. 2019-01-16
Mecuris–Vesalius Biocapital: investment, 201901 financing round Series A totalling €3.6m incl new investor Vesalius Biocapital III SICAR 2019-01-16
United States (govt)–Valneva: Japanese encephalitis vaccine, 201901– supply $59m+$11m of Ixiaro to US DoD 2019-01-16
Boehringer–Bioharmony Therapeutics: antibiotics, 201901– collab developm of bateriophage lysins 2019-01-15
InterAx Biotech–Falcon III Ventures: investment, 201901 financing round totalling CHF3m incl co-lead investor Falcon III Ventures 2019-01-15
InterAx Biotech–SEVERAL: investment, 201901 financing round CHF3m led by Falcon III Ventures + Investiere 2019-01-15
InterAx Biotech–Verve Capital Partners: investment, 201901 financing round totalling CHF3m incl co-lead investor Investiere 2019-01-15
Cell Signaling Technology–Omni Life Science: cell research instruments, 201901– distribution of OLS’ CERO + CESY instruments by Bioké in Benelux 2019-01-14
Merck (DE)–Roche: biochemical reagents, 201901–2025 distribution extension ww excl of Roche biochemical reagents portfolio 2019-01-14
Agenus–JSR Corp: cell line development, 201901– collab expansion license to use Selexis’ SUREtechnology for production of therapeutic proteins 2019-01-09
BC Platforms–MedEngine (FI): medical data science services, 201901– collab strategic partnership to provide solutions for pharma + health sectors 2019-01-09
Denali Therapeutics–Sirion Biotech: gene delivery technology, 201901– license + collab develop AAV vectors for CNS diseases that could cross BBB 2019-01-09
CureVac–Global Health PR: public relations, 201809 service existent media relations by Global Health PR 2019-01-08
Exscientia–Celgene: investment, 201901 financing round Series B totalling $26m incl new investor Celgene Corp 2019-01-07
Exscientia–Evotec: investment, 201901 financing round Series B totalling $26m incl $6m from existing investor Evotec AG 2019-01-07
Exscientia–GT Healthcare Capital Partners: investment, 201901 financing round Series B totalling $26m incl new investor GT Healthcare Capital Partners 2019-01-07
Exscientia–SEVERAL: investment, 201901 financing round Series B $26m incl Celgene Corp + GT Heallthcare Capital Partners + Evotec 2019-01-07
F2G Ltd–Optimum Strategic Communications: public relations, 201901 service existent by Optimum 2019-01-07
Immunic–SEVERAL: investment, 201901–201904 financing round €26.7m in connection with reverse merger to list on Nasdaq 2019-01-07
Immunic–Vital Therapeutics: investment, 201901–201904 reverse merger to list on Nasdaq with Vital Therapies renamed Immunic Inc 2019-01-07
Loxo Oncology–Lilly: investment, 201901–201902 acquisition cash tender offer $8b for $235/share 2019-01-07
N-of-One–Qiagen: investment, 201901 acquisition €na of N-of-One Inc by Qiagen 2019-01-07
Roche–Exscientia: drug discovery software, 201901– collab up to CHF67m + royalties using Centaur Chemist to design drug candidates 2019-01-07
Biogen–C4 Therapeutics: neurological drugs, 201901– collab strategic up to $415m upfront/milestones discovery small molecues for protein degradation 2019-01-04
Biogen–Skyhawk Therapeutics: neurological drugs, 201901– collab strategic $74m upfront + milestones discovery small molecues using SkySTAR platform 2019-01-04
Medigene–Helmholtz: cell therapy, 201901– license to co-stimulator to enhance TCR therapies for solid tumours from HMGU 2019-01-04
Ribon Therapeutics–Celgene: investment, 201901 financing round Series B totalling $65m incl new + co-investor Celgene Corp 2019-01-04
Ribon Therapeutics–Column Group: investment, 201901 financing round Series B totalling $65m incl existing + co-investor The Column Group 2019-01-04
Ribon Therapeutics–Deerfield: investment, 201901 financing round Series B totalling $65m incl existing + co-investor Deerfield Management 2019-01-04
Ribon Therapeutics–Euclidean Capital: investment, 201901 financing round Series B totalling $65m incl existing + co-investor Euclidean Capital 2019-01-04
Ribon Therapeutics–JnJ: investment, 201901 financing round Series B totalling $65m incl new + co-investorJJDC 2019-01-04
Ribon Therapeutics–Novartis: investment, 201901 financing round Series B totalling $65m incl new + lead investor Novartis Venture Fund 2019-01-04
Ribon Therapeutics–Osage Partners: investment, 201901 financing round Series B totalling $65m incl existing + co-investor Osage University Partners 2019-01-04
Ribon Therapeutics–SEVERAL: investment, 201901 financing round Series B $65m led by Novartis Venture Fund 2019-01-04
Ribon Therapeutics–Takeda: investment, 201901 financing round Series B totalling $65m incl existing + co-investor Takeda Ventures 2019-01-04
Ribon Therapeutics–US Venture Partners: investment, 201901 financing round Series B totalling $65m incl existing + co-investor US Venture Partners 2019-01-04
Sophia Genetics–Alychlo: investment, 201901 financing round Series E totalling $77m incl existing + co-investor Alychlo 2019-01-04
Sophia Genetics–Balderton Capital: investment, 201901 financing round Series E totalling $77m incl existing + co-investor Balderton Capital 2019-01-04
Sophia Genetics–Eurazeo: investment, 201901 financing round Series E totalling $77m incl new + co-investor Idinvest Partners 2019-01-04
Sophia Genetics–Generation Investment Management: investment, 201901 financing round Series E totalling $77m incl new + lead investor Generation 2019-01-04
Sophia Genetics–SEVERAL: investment, 201901 financing round Series E $77m incl new + lead investor Generation Investment Management LLP 2019-01-04
Atriva Therapeutics–High-Tech Gründerfonds: investment, 201901 financing round Series A first closing led by Meneldor + HTGF 2019-01-03
Atriva Therapeutics–MC Services: public relations, 201901 service existent by MC Services 2019-01-03
Atriva Therapeutics–Meneldor: investment, 201901 financing round Series A first closing led by Meneldor + HTGF 2019-01-03
Atriva Therapeutics–SEVERAL: investment, 201901 financing round Series A first closing led by Meneldor + HTGF 2019-01-03
Takeda–Rentschler: biologics contract manufacturing, 201901– supply service continued production for Shire in acquired manufacturing site in Milford 2019-01-03
CARB-X–Germany (govt): grant, 201901–202212 BMBF commits €40m over 4 years 2019-01-01
Curetis–Vienna (govt): grant, 201901–202106 co-funding of developm project of Ares Genetics for AMR assay by Vienna Business Agency 2019-01-01
Marinomed–EU (govt): credit, 20901–2027 up to €15m EIB credit 2019–2022 repayable 2024–2027 2019-01-01
Blink Biomedical–Valneva: investment, 201812 existing shareholding of 43.3% by Valneva consolidated via equity method 2018-12-31
Murdoch Univ–Bruker: mass spectrometer, 2018–201909 supply FIA-MRMS system 2018-12-31
Murdoch Univ–Bruker: mass spectrometer, 2018–201909 supply twelve impact-II UHR-QTOF LC-MS/MS systems 2018-12-31
Murdoch Univ–Bruker: mass spectrometer, 2018–201909 supply two timsTOF Pro LC/CCS/MS/MS systems 2018-12-31
Murdoch Univ–Bruker: NMR spectrometer, 2018–201909 supply seven Avance IVDr 600 NMR systems 2018-12-31
Qiagen–Formulatrix: digital PCR technology, 201812– acquisition of all dPCR assets of Formulatrix for $125m upfront cash + $135m milestones 2018-12-31
Harpoon Therapeutics–SEVERAL: investment, 201812–201902 IPO $76m at $14/share 2018-12-27
Nabriva–Hercules Technology: credit, 201812–202306 term loan up to $75m with $25m up front von Hercules Capital 2018-12-21
Evitria–Afinum: investment, 201812 acquisition majority stake by Afinum Achte Beteiligungs GmbH & Co KG + SHS V Medtech Investments GmbH 2018-12-20
Evitria–SHS: investment, 201812 acquisition majority stake by Afinum Achte Beteiligungs GmbH & Co KG + SHS V Medtech Investments GmbH 2018-12-20
France (govt)–Novartis: investment, 201812– proposed acquisition of CellforCure from LFB by Novartis 2018-12-20
AC Immune–WuXi Pharmatech: biologics contract manfucturing, 201812– collab strategic alliance biologics CDMO with WuXi Biologics 2018-12-19
Annexon–Novartis: investment, 201812 financing round Series C totalling $75m incl exisiting + co-investor NVF 2018-12-19
Annexon–SEVERAL: investment, 201812 financing round Series C $75m led by new investor Bain Capital Life Sciences 2018-12-19
Cellestia Biotech–PPF Group: investment, 201812 financing round Series A totalling CHF20m incl existing + co-lead investor Sotio/PPF Group 2018-12-19
Cellestia Biotech–SEVERAL: investment, 201812 financing round Series A CHF20m from FC Capital + Sotio/PPF Group + ETP Ventures + private investors 2018-12-19
Amgen–Molecular Partners: cancer immunotherapy, 201812– collab $50m upfront + $497m milestones + royalties ww excl developm + commerc rights to MP0310 2018-12-18
Novartis–Curetis: antibiotics research, 201812– collab Sandoz to use Ares Genetics’ antibiotic resistance database ARESdb 2018-12-18
PreOmics–High-Tech Gründerfonds: investment, 201812 financing round Series A totalling €3.3m incl HTGF + Think.Health Ventures + business angels 2018-12-18
PreOmics–SEVERAL: investment, 201812 financing round Series A €3.3m from HTGF + Think.Health Ventures + business angels 2018-12-18
PreOmics–Think.Health Ventures: investment, 201812 financing round Series A totalling €3.3m incl HTGF + Think.Health Ventures + business angels 2018-12-18
Versameb–SEVERAL: investment, 201812 colsing of seed B financing round brining total capital raised to date to CHF5.3m 2018-12-18
Seer–Invus Group: investment, –201812 financing rounds Series A + B totalling $36m incl Series B lead investor Invus 2018-12-17
Seer–Maverick Ventures: investment, –201812 financing rounds Series A + B totalling $36m incl Series A lead investor Maverick Ventures 2018-12-17
Seer–SEVERAL: investment, –201812 financing rounds Series A + B of $36m until 12/18 as company emerges from stealth 2018-12-17
Shire–Rentschler: investment, 201812–201901 acquisition €na of Shire’s manufacturing facility in Milford, MA by Rentschler Biopharma SE 2018-12-17
Orchard Therapeutics–Sirion Biotech: gene therapy manufacturing technology, 201812– license for stem cell gene therapies 2018-12-14
Lonza–ERS Genomics: CRISPR technology, 201812– license €na for bioproduction products + services + iPSC research to Lonza Pharma & Biotech 2018-12-13
Mestrelab Research–Bruker: investment, 201812 acquisition of majority share €na by Bruker incl strateg collab + partnership 2018-12-13
AC Immune–Lilly: credit, 201812 convertible note $50m in connection with license + collab agreement 2018-12-12
Imprint Analytics–SGS: credit, 201812– convertible loan as part of strategic partnership 2018-12-12
Lilly–AC Immune: tau aggregation inhibitors, 201812– collab + license agreem CHF80m upfront + CHF1.76b milestones + royalties 2018-12-12
Santhera–SEVERAL: investment, 201812 capital increase CHF23.5m with 3.134m shares at CHF7.5/share 2018-12-12
SGS–Imprint Analytics: food analysis, 201812– collab strategic partnership isotope analysis for proof of origin + authenticity food testing 2018-12-12
DenovoMatrix–High-Tech Gründerfonds: investment, 201812 seed financing round from HTGF + TGFS 2018-12-11
DenovoMatrix–Saxony (govt): investment, 201812 seed financing round from HTGF + TGFS 2018-12-11
DenovoMatrix–SEVERAL: investment, 201812 seed financing round from HTGF + TGFS 2018-12-11
Chiesi–Centogene: genetic services, 201812– collab epidemiology study in lysosomal storage diseases with focus on AM by Centogene for Chiesi GmbH 2018-12-10
genOway–Merck (DE): CRISPR technology, 201812– collab strategic alliance €na incl ww excl license to produce + sell genome-edited rodent models 2018-12-10
genOway–Merck (DE): CRISPR technology, 202001– collab strategic alliance extention incl adding non-excl license for all non-rodent animal cell models 2018-12-10
next pagenext page 1 2 3 ... 12 13 14 ... 30 31 32  next pagenext page



Advertisement

Picture [iito] Männer Ballett 650x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [iito] Made Without Love 650x80px

» top